aztreonam has been researched along with Sepsis in 40 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aztreonam was used in the initial treatment of infection of the urinary tract (23 cases), respiratory tract (17 cases), skin and soft tissue (12 cases), abdominal cavity (three cases), endocarditis (two cases), septicemia (eight cases), and osteomyelitis (two cases)." | 5.27 | Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. ( Chandrasekar, P; Kannangara, W; LeFrock, JL; Molavi, A; Rolston, KV; Smith, BR, 1987) |
| "Two similar cohorts of low birth weight infants whose size was appropriate for gestational age randomly received either aztreonam-arginine plus ampicillin (n = 15) or gentamicin plus ampicillin (n = 15) for empiric treatment of neonatal sepsis." | 5.07 | Metabolic tolerance to arginine: implications for the safe use of arginine salt-aztreonam combination in the neonatal period. ( Argyle, C; McCracken, G; Mize, C; Uauy, R, 1991) |
| "Multicenter trials were conducted to determine the safety and efficacy of aztreonam in the treatment of patients with gram-negative bacterial infections." | 5.05 | Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. ( Bendush, CB; Henry, SA, 1985) |
| " An adequate standard dosage of aztreonam could be established as 3-4 g/day in compromised patients, and it should be combined with gram-positive coverage when used empirically." | 2.66 | A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients. ( Bosch-Perez, A; Rabinad, E, 1989) |
| "Aztreonam-treated patients are free of nephrotoxicity but are at risk of enterococcal superinfections." | 2.66 | Comparative clinical evaluation of aztreonam versus aminoglycosides in gram-negative septicaemia. ( Ariza, X; Fernández-Viladrich, P; Gudiol, F; Liñares, J; Pallarés, R; Rufi, G, 1986) |
| "Aztreonam has proven to be effective, safe therapy for serious and life-threatening infections caused by multiresistant aerobic gram negative bacteria." | 2.37 | Aztreonam: the first monobactam. ( Neu, HC, 1988) |
| "In addition, combined treatments of bacterial infections should allow for a reduction in dosages of antibiotics while at the same time, achieving increased efficacy." | 1.28 | Potentiation by nonspecific immunostimulation of the efficacy of antibiotics in the treatment of experimental bacterial infections. ( Bizzini, B; Fattal-German, M, 1989) |
| "Aztreonam was administered to 25 neonates (16 term, 9 premature) with clinically and bacteriologically proved gram-negative infections." | 1.28 | Successful response of severe neonatal gram-negative infection to treatment with aztreonam. ( Constantopoulos, A; Loupa, H; Papoulias, G; Thomaidou, L, 1989) |
| "Aztreonam was used for a year to treat 106 hospitalized patients with a total of 131 documented gram-negative infections." | 1.27 | Treatment of serious gram-negative infections with aztreonam. ( Bollinger, M; Darji, TB; Greenberg, RN; Luppen, KL; McMillian, R; Noorani, AA; Reilly, PM; Wolk, SM, 1984) |
| "Carumonam is a new N-sulfo-beta-lactam antibiotic active against aerobic Gram-negative bacteria." | 1.27 | Clinical efficacy of carumonam. ( Blakemore, PH; Drabu, YJ; Mehtar, S, 1988) |
| "Aztreonam was given i." | 1.27 | Aztreonam in the treatment of serious gram-negative infections in the elderly. ( Deger, F; Douchamps, J; Freschi, E; Herchuelz, A; Nève, P; Thys, JP, 1988) |
| "Aztreonam may prove to be an effective alternative for the treatment of gram-negative septicemia, but superinfections should be carefully monitored." | 1.27 | Aztreonam treatment of gram-negative septicemia. ( Boelaert, J; Huyghens, L; Lauwers, S; Naessens, A; Pierard, D; Van Landuyt, HW, 1986) |
| "Aztreonam was used in the initial treatment of infection of the urinary tract (23 cases), respiratory tract (17 cases), skin and soft tissue (12 cases), abdominal cavity (three cases), endocarditis (two cases), septicemia (eight cases), and osteomyelitis (two cases)." | 1.27 | Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. ( Chandrasekar, P; Kannangara, W; LeFrock, JL; Molavi, A; Rolston, KV; Smith, BR, 1987) |
| "Carumonam was intermediate between ceftazidime and aztreonam as to the activity against Pseudomonas aeruginosa." | 1.27 | Antibacterial properties of carumonam (Ro 17-2301, AMA-1080), a new sulfonated monocyclic beta-lactam antibiotic. ( Angehrn, P, 1985) |
| "Aztreonam is a novel antimicrobial agent belonging to the monobactam class of antibiotics." | 1.27 | Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. ( Neu, HC; Scully, BE, 1985) |
| "Aztreonam is a monocyclic beta-lactam antibiotic that inhibits aerobic gram-negative bacilli, including beta-lactamase-producing species." | 1.27 | Current state of infectious diseases--potential areas of directed therapy with aztreonam. ( Neu, HC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (60.00) | 18.7374 |
| 1990's | 6 (15.00) | 18.2507 |
| 2000's | 4 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, W | 1 |
| Xiong, L | 1 |
| Luo, Q | 1 |
| Chen, Y | 1 |
| Ji, J | 1 |
| Ying, C | 1 |
| Liu, Z | 1 |
| Xiao, Y | 1 |
| Zhang, L | 1 |
| Zhen, S | 1 |
| Shen, Y | 1 |
| Zhang, T | 1 |
| Wang, J | 2 |
| Li, J | 1 |
| Lin, Q | 1 |
| Xiao, Z | 1 |
| Zheng, Y | 1 |
| Jiang, E | 1 |
| Han, M | 1 |
| Feng, S | 1 |
| Lu, B | 1 |
| Wang, B | 1 |
| Pan, X | 1 |
| Liu, C | 1 |
| Jin, C | 1 |
| Shi, Y | 1 |
| Zhou, Y | 1 |
| Sieswerda, E | 1 |
| van den Brand, M | 1 |
| van den Berg, RB | 1 |
| Sträter, J | 1 |
| Schouls, L | 1 |
| van Dijk, K | 1 |
| Budding, AE | 1 |
| Miller, J | 1 |
| Hall, B | 1 |
| Wilson, K | 1 |
| Cobian, J | 1 |
| Falcone, M | 1 |
| Daikos, GL | 1 |
| Tiseo, G | 1 |
| Bassoulis, D | 1 |
| Giordano, C | 1 |
| Galfo, V | 1 |
| Leonildi, A | 1 |
| Tagliaferri, E | 1 |
| Barnini, S | 1 |
| Sani, S | 1 |
| Farcomeni, A | 1 |
| Ghiadoni, L | 1 |
| Menichetti, F | 1 |
| Araoka, H | 1 |
| Baba, M | 1 |
| Tatsushima, K | 1 |
| Takagi, S | 1 |
| Matsuno, N | 1 |
| Wake, A | 1 |
| Taniguchi, S | 1 |
| Yoneyama, A | 1 |
| Sklavunu-Tsurutsoglu, S | 2 |
| Gatzola-Karaveli, M | 2 |
| Hatziioannidis, K | 1 |
| Tsurutsoglu, G | 2 |
| Machado, DP | 1 |
| Nunes, FB | 1 |
| Simões Pires, MG | 1 |
| D'Avila, LC | 1 |
| Leite, CE | 1 |
| Ruschel, RE | 1 |
| da Cunha, AA | 1 |
| Saciura, VC | 1 |
| Poloni, JA | 1 |
| Lunardelli, A | 1 |
| de Oliveira, JR | 1 |
| Alves Filho, JC | 1 |
| Cunha, FQ | 1 |
| Dias, FS | 1 |
| Poli de Figueiredo, CE | 1 |
| Jaber, A | 1 |
| Nong, M | 1 |
| Thiagarajan, P | 1 |
| San Joaquin, VH | 1 |
| Stutman, HR | 2 |
| Marks, MI | 2 |
| Greenberg, RN | 1 |
| Reilly, PM | 1 |
| Luppen, KL | 1 |
| McMillian, R | 1 |
| Bollinger, M | 1 |
| Wolk, SM | 1 |
| Darji, TB | 1 |
| Noorani, AA | 1 |
| Toyama, K | 1 |
| Yaguchi, M | 1 |
| Mizoguchi, H | 1 |
| Masuda, M | 1 |
| Urabe, A | 1 |
| Ikeda, Y | 1 |
| Aoki, I | 1 |
| Shinbo, T | 1 |
| Togawa, A | 1 |
| Hirashima, K | 1 |
| Miura, Y | 1 |
| Hirose, S | 1 |
| Tsuruoka, N | 1 |
| Omine, M | 1 |
| Kamakura, M | 1 |
| Saito, T | 1 |
| Arimori, S | 1 |
| Aoki, N | 1 |
| Kuraishi, Y | 1 |
| Hirai, H | 1 |
| Asano, S | 1 |
| Mori, M | 1 |
| Shirai, T | 1 |
| Muto, Y | 1 |
| Takaku, F | 1 |
| Mercer-Jones, MA | 1 |
| Hadjiminas, DJ | 1 |
| Heinzelmann, M | 1 |
| Peyton, J | 1 |
| Cook, M | 1 |
| Cheadle, WG | 1 |
| Gilad, J | 1 |
| Borer, A | 1 |
| Peled, N | 1 |
| Riesenberg, K | 1 |
| Tager, S | 1 |
| Appelbaum, A | 1 |
| Schlaeffer, F | 1 |
| Sakata, Y | 1 |
| Sawada, Y | 1 |
| Kuroe, K | 1 |
| Nakaji, S | 1 |
| Takami, H | 1 |
| Tsushima, K | 1 |
| Saito, S | 1 |
| Ogasawara, H | 1 |
| Shinagawa, H | 1 |
| Soma, N | 1 |
| Wu, SW | 1 |
| Dornbusch, K | 1 |
| Göransson, E | 1 |
| Ransjö, U | 1 |
| Kronvall, G | 1 |
| Uauy, R | 1 |
| Mize, C | 1 |
| Argyle, C | 1 |
| McCracken, G | 1 |
| Spencer, RC | 1 |
| Taylor, AK | 1 |
| Winfield, DA | 1 |
| Bizzini, B | 1 |
| Fattal-German, M | 1 |
| Rabinad, E | 2 |
| Bosch-Perez, A | 1 |
| Constantopoulos, A | 1 |
| Thomaidou, L | 1 |
| Loupa, H | 1 |
| Papoulias, G | 1 |
| Farid, Z | 1 |
| Girgis, NI | 1 |
| Abu el Ella, AH | 1 |
| el-Messidi, M | 1 |
| Dessouki, A | 1 |
| Woody, J | 1 |
| Drabu, YJ | 1 |
| Mehtar, S | 1 |
| Blakemore, PH | 1 |
| Neu, HC | 3 |
| Mozzillo, N | 1 |
| Formato, A | 1 |
| Ottaviano, A | 1 |
| Romano, A | 1 |
| Craus, W | 1 |
| Dalet, F | 1 |
| del Río, G | 1 |
| Deger, F | 1 |
| Douchamps, J | 1 |
| Freschi, E | 1 |
| Thys, JP | 1 |
| Nève, P | 1 |
| Herchuelz, A | 1 |
| Wood, MJ | 1 |
| Smith, G | 1 |
| Farrell, ID | 1 |
| Hitoglu-Makedu, A | 1 |
| Paradelis, AG | 1 |
| Lagast, H | 1 |
| Klastersky, J | 1 |
| Kains, JP | 1 |
| van der Auwera, P | 1 |
| Meunier, F | 1 |
| Woussen, F | 1 |
| Thijs, JP | 1 |
| Pierard, D | 1 |
| Boelaert, J | 1 |
| Van Landuyt, HW | 1 |
| Naessens, A | 1 |
| Huyghens, L | 1 |
| Lauwers, S | 1 |
| Gudiol, F | 1 |
| Pallarés, R | 1 |
| Ariza, X | 1 |
| Fernández-Viladrich, P | 1 |
| Rufi, G | 1 |
| Liñares, J | 1 |
| Chartrand, SA | 1 |
| Tolentino, T | 1 |
| Friedhoff, L | 1 |
| LeFrock, JL | 1 |
| Smith, BR | 1 |
| Chandrasekar, P | 1 |
| Rolston, KV | 1 |
| Molavi, A | 1 |
| Kannangara, W | 1 |
| Henry, SA | 1 |
| Bendush, CB | 1 |
| Starr, SE | 1 |
| Angehrn, P | 1 |
| Scully, BE | 1 |
3 reviews available for aztreonam and Sepsis
| Article | Year |
|---|---|
Hospital-acquired brevundimonas vesicularis septicaemia following open-heart surgery: case report and literature review.
Topics: Adult; Anti-Infective Agents; Aztreonam; Ciprofloxacin; Cross Infection; Female; Humans; Microbial S | 2000 |
Aztreonam: the first monobactam.
Topics: Aztreonam; Bacterial Infections; Gram-Negative Bacteria; Humans; Respiratory Tract Infections; Sepsi | 1988 |
Antimicrobial therapy of bacterial sepsis in the newborn infant.
Topics: Aminoglycosides; Ampicillin; Anti-Bacterial Agents; Aztreonam; Bacteria; Cephalosporins; Cross Infec | 1985 |
9 trials available for aztreonam and Sepsis
| Article | Year |
|---|---|
Effect of recombinant human granulocyte colony-stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Clindamycin; Drug Therapy, Com | 1996 |
[A randomized controlled study on imipenem/cilastatin sodium in comparison to aztreonam + lincomycin in treating severe infections in patients with malignant tumors or hematological diseases].
Topics: Adolescent; Adult; Aged; Aztreonam; Cilastatin; Drug Therapy, Combination; Female; Hematologic Disea | 1992 |
Metabolic tolerance to arginine: implications for the safe use of arginine salt-aztreonam combination in the neonatal period.
Topics: Ammonia; Ampicillin; Analysis of Variance; Arginine; Aztreonam; Bilirubin; Blood Glucose; Cohort Stu | 1991 |
A comparative efficacy and safety study of teicoplanin plus aztreonam versus gentamicin plus piperacillin in haematology oncology patients with clinically diagnosed septicaemia.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Bacteria; Drug Therapy, Combination; Female; Gentamicins; G | 1990 |
A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacterial Infecti | 1989 |
Antibiotic prophylaxis in surgery ranked by patients' risk rates.
Topics: Aztreonam; Clindamycin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Gentamicins; Hu | 1987 |
Empiric antimicrobial therapy with aztreonam or ceftazidime in gram-negative septicemia.
Topics: Adult; Aged; Aztreonam; Blood Bactericidal Activity; Ceftazidime; Enterobacteriaceae Infections; Fem | 1986 |
Comparative clinical evaluation of aztreonam versus aminoglycosides in gram-negative septicaemia.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Female; Gram-Negative Bacteria; Huma | 1986 |
Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
Topics: Abdomen; Adult; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Clini | 1985 |
28 other studies available for aztreonam and Sepsis
| Article | Year |
|---|---|
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Carbapenems; Ceftazidime; D | 2021 |
Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options.
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Drug Combina | 2023 |
First case of bloodstream infection caused by NDM-positive Escherichia hermannii.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Humans; Male; Microbial Sensitivity Tests; | 2023 |
Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftazidime; Drug Combinati | 2020 |
Impact of SEP-1 on broad-spectrum combination antibiotic therapy in the emergency department.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Centers for Medicare and Medi | 2020 |
Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftazidime; Drug Combinati | 2021 |
[Case of sepsis caused by multidrug-resistant neutropenic-phase Pseudomonas aeruginosa treated successfully with antibiotic combination therapy].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Drug Resistance, Multiple; Drug Therapy, Combination; Hu | 2008 |
Aztreonam treatment of neonatal sepsis.
Topics: Anti-Bacterial Agents; Aztreonam; Birth Weight; Gram-Negative Bacterial Infections; Humans; Infant; | 1989 |
Effects of beta-lactam antibiotics and L-arginine in the treatment of experimental sepsis in rats.
Topics: Animals; Arginine; Ascitic Fluid; Aztreonam; beta-Lactams; Ceftriaxone; Drug Therapy, Combination; I | 2006 |
Transient neutrophilic thrombophagocytosis associated with Citrobacter freundii septicemia.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; Citrobacter freundii; Enterobacteriaceae Infections; Humans; | 2006 |
Hemophilus influenzae type b meningitis in infant rabbits. Pathogenesis and therapy.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Animal; Haemophilus Infections; Half-Life | 1984 |
Treatment of serious gram-negative infections with aztreonam.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Drug Evaluation; En | 1984 |
Continuous antibiotic treatment for experimental abdominal sepsis: effects on organ inflammatory cytokine expression and neutrophil sequestration.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Cefoxitin; Cephamycins; Cytokines; Endotoxins; Interleuki | 1998 |
Characterization of Klebsiella oxytoca septicaemia isolates resistant to aztreonam and cefuroxime.
Topics: Aztreonam; beta-Lactamases; Cefuroxime; DNA, Bacterial; Drug Resistance, Microbial; Humans; Klebsiel | 1991 |
Potentiation by nonspecific immunostimulation of the efficacy of antibiotics in the treatment of experimental bacterial infections.
Topics: Adjuvants, Immunologic; Ampicillin; Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; | 1989 |
Successful response of severe neonatal gram-negative infection to treatment with aztreonam.
Topics: Aztreonam; Bacterial Infections; Gram-Negative Bacteria; Humans; Infant, Newborn; Infant, Premature, | 1989 |
Aztreonam in the treatment of enteric fevers.
Topics: Adolescent; Adult; Aztreonam; Child; Female; Humans; Male; Paratyphoid Fever; Salmonella paratyphi A | 1987 |
Clinical efficacy of carumonam.
Topics: Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Female; Gram-Negative Aerobic Bacteria; Hu | 1988 |
[Aztreonam: prevention of bacteremia in urologic surgery in patients with urinary infection].
Topics: Adult; Aged; Aztreonam; Female; Gram-Negative Bacteria; Humans; Male; Middle Aged; Postoperative Com | 1988 |
Aztreonam in the treatment of serious gram-negative infections in the elderly.
Topics: Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Female; Gram-Negative Aerobic Bacteria; Hu | 1988 |
Aztreonam for severe infections.
Topics: Aztreonam; Bacterial Infections; Female; Humans; Male; Middle Aged; Sepsis; Urinary Tract Infections | 1987 |
Aztreonam in gram-negative infections in children.
Topics: Aztreonam; Bacterial Infections; Child; Child, Preschool; Female; Gram-Negative Bacteria; Humans; In | 1987 |
Aztreonam treatment of gram-negative septicemia.
Topics: Adolescent; Adult; Aged; Aztreonam; Female; Gram-Negative Bacteria; Humans; Male; Middle Aged; Sepsi | 1986 |
Aztreonam therapy for serious gram-negative infections in children.
Topics: Aztreonam; Bacteria, Aerobic; Bacterial Infections; Child, Preschool; Humans; Infant; Infant, Newbor | 1986 |
Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Female; Gram-Negative Bacteria; Hum | 1987 |
Antibacterial properties of carumonam (Ro 17-2301, AMA-1080), a new sulfonated monocyclic beta-lactam antibiotic.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacteria; Enterobacteriaceae; Escherichia coli Infections | 1985 |
Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infectio | 1985 |
Current state of infectious diseases--potential areas of directed therapy with aztreonam.
Topics: Abdomen; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Biliary Trac | 1985 |